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The timely and accurate identification of adverse drug reactions (ADRs) following drug approval is a
persistent and serious public health challenge. Aggregated data drawn from anonymized logs of Web
searchers has been shown to be a useful source of evidence for detecting ADRs. However, prior studies
have been based on the analysis of established ADRs, the existence of which may already be known pub-
lically. Awareness of these ADRs can inject existing knowledge about the known ADRs into online content
and online behavior, and thus raise questions about the ability of the behavioral log-based methods to
detect new ADRs. In contrast to previous studies, we investigate the use of search logs for the early
detection of known ADRs. We use a large set of recently labeled ADRs and negative controls to evaluate
the ability of search logs to accurately detect ADRs in advance of their publication. We leverage the
Internet Archive to estimate when evidence of an ADR first appeared in the public domain and adjust
the index date in a backdated analysis. Our results demonstrate how search logs can be used to detect
new ADRs, the central challenge in pharmacovigilance.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Adverse drug reactions (ADRs) are the fourth leading cause of
death in the United States, ahead of pulmonary disease, diabetes,
infection with human immunodeficiency virus, and automobile
accidents [1–4]. Pharmacovigilance centers on the assessment, pre-
vention, monitoring, and detection of ADRs in the post-marketing
period (i.e., after the medication has been released to market and
is being used by patients). Mining evidence of ADRs from various
data sources to identify previously unknown ADRs is a central goal
of pharmacovigilance [4].
The United States Food and Drug Administration (FDA) receives
information about post-marketing ADRs via spontaneous reports
submitted by healthcare professionals. The FDA’s Adverse Event
Reporting System (FAERS) pools these reports and these data are
routinely analyzed to identify signals of new ADRs [5,6]. Significant
evidence of ADRs drawn from spontaneous reports in FAERS may
lead to deeper investigations followed by regulatory actions suchas a drug withdrawal from the market, the issuance of public
warnings, and/or enforcement of changes to the label that appears
on the packaging (i.e., label changes). Beyond spontaneous reports,
other data have also been employed to develop more capable and
robust systems for pharmacovigilance purposes. These additional
sources include electronic health records and medical insurance
claims [7–9], findings published in the biomedical literature
[10–12], as well as other sources such as chemical and biological
knowledge bases [13,14]. Pharmaceutical companies also perform
post-marketing safety surveillance to understand the long-term
effects of their products and to discover less frequent ADRs that
are not identified in clinical trials.
Non-traditional sources such as logs of search engine activity or
social media (e.g., postings on online forums and social networks)
contain evidence of health-related issues [15] and may provide
new insights in support of early detection of ADRs. These sources
are currently being studied as additional inputs for signal detection
[4,16–18]. People have been shown to consistently search the
Internet for health-related matters. A 2013 study by the Pew
Research Center found that 72% of Internet users claimed to search
online for health information and that 8 in 10 online health
inquiries start at a search engine [19]. Search logs are used in the
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influenza-related search terms recorded by search engines can be
used to provide fast-paced updates on rates of influenza [20].
Recently, search logs have been shown to be effective in identifying
ADRs and interactions between medications [21–23], as well as a
complement to more traditional methods of mining ADRs based
on spontaneous reporting [22].
We consider a set of recent label changes for our study of the
early identification of ADRs from logs of Web search activity.
Specifically, we consider the medications that are the focus of
attention, the ADR added during a label change for that medication,
and the date that this label change occurred (hereafter referred to
as the index date) as ground truth data for our study of the early
identification of ADRs. We use anonymized large-scale search
engine query log data from consenting users of the Microsoft Bing
Web search engine. Search logs may reveal concerns about
observed side effects of medications in advance of traditional
reporting by physicians and patients. Despite the promise of search
services to provide signals about such concerns on a wide scale,
analyses of aggregate signals of online human behavior in the
absence of more detailed interviews pose multiple statistical chal-
lenges. For example, the frequencies of terms used in searches may
be significantly influenced by media coverage [24], related pan-
demics, e.g., H1N1 (swine flu) [25], and changes in search engine
ranking functions [26] and data capture policies.
A key challenge in assessing the power of using aggregate
online behavior to detect previously unknown ADRs is accounting
for the potential leak of existing ADR reports and knowledge onto
the Web. ADR information may appear on Websites such as social
media before the publication of FDA label changes and affect peo-
ple’s search actions via factors such as information cascades
[27,28]. Studies to date have explored the detection of ADRs that
were known at analysis time, using reference standards such as
those from the Observable Medical Outcomes Partnership (OMOP)
[29] and the European Union EU-ADR [8] projects, designed for the
retrospective evaluation of ADR detection methods using health
records. The public availability and awareness of knowledge about
ADRs may affect spontaneous reporting rates for those ADRs or
prescription patterns, which in turn could bias retrospective eval-
uations [16,30]. Interest demonstrated by users via queries to Web
search engines using terms associated with ADRs may be
prompted by existing online content rather than personal
experiences with side effects. To be a truly useful mechanism,
pharmacovigilance systems need to accurately predict emerging
and unknown ADRs in advance of slower processes involving the
curation of medical reports [30,31].
We created as a benchmark a time-indexed reference set of
ADRs recently labeled by the FDA (and matching negative controls)
[32]. We used this reference set to evaluate the ability of search
logs to detect ADRs in advance of their publication by backdating
the signal detection analysis to periods prior to their publication.
Signals derived from Microsoft Bing search log data collected over
a period of three years were used as the basis for our analysis. We
combined logged data on searches and snapshots of Web page con-
tent from the Wayback Machine provided by the Internet Archive
(archive.org), a non-profit organization that stores periodic snap-
shots of Web content. The Wayback Machine was used to assess
conservatively the date of the appearance of any evidence related
to knowledge or suspicions of drug–ADR associations in online
content. These dates serve as index dates for backdating analyses
to limit the influence of existing Web page content associated with
ADRs on analyzed queries. Such dates could be earlier than the
dates on which our ADRs were added to medication labels by the
FDA. If so, we use those earlier dates as the index dates in our
analysis.2. Materials and methods
2.1. Search log data
We used three full years of log data collected from consenting
users of the Microsoft Bing search engine during 2011–2013 as
the basis for the study. The data collection and portions of the anal-
ysis was undertaken as part of the Bing Predicts project within the
Microsoft Bing search engine. These logs contained users’ search
queries, a timestamp for when each query was issued (in the user’s
local timezone), and a unique identifier for the user which could be
used to associate queries with a particular user over time. We used
longitudinal analysis of search behavior in these logs as the basis
for the early detection of ADRs for medications. Although the logs
span a period of three years, any single user appears in the logs for
at most 18 months, conforming to the terms of use under which
the data were collected.
All data access and analysis was done in accordance with the
search engine’s published end-user license agreement, which spec-
ifies that user data may be used for research purposes and to
improve the search experience. Our work was conducted offline,
on data collected to support existing business operations, and in
no way impacted the presentation of search results or other
aspects of the user experience. All data were anonymized (such
that users cannot be identified, directly or through identifiers
linked to them) prior to data analyses. The Ethics Advisory Com-
mittee at Microsoft Research considers these precautions sufficient
for triggering the Common Rule, exempting this research from
detailed ethics review.
To ensure that we had sufficient data to perform our within-
user long-term analysis, we focused on users in our dataset for
whom we had observed at least 100 search sessions, yielding
57,101,343 users in total. Our unique user identifiers were based
on Web browser cookies and were reset when users cleared their
cookies. As such, we focused on users for whom we had more com-
plete data on their long-term behavior. We experimented with dif-
ferent session-count thresholds, ranging from 1 to 200 search
sessions. A threshold of 100 sessions yielded strong performance
at the early detection task, while still retaining sufficient users to
cover a sizeable set of drug–ADR pairs. Sessions were identified
using a 30-min inactivity timeout to define session termination,
a threshold commonly employed in research on user modeling in
search logs [33,34]. Users linked to P1000 search queries on any
given day were classified as automated traffic (Internet bots) and
removed. In previous work [22], we found that the percentage of
a user’s queries that contained a medical term within their first
month of search activity could help identify healthcare profession-
als (HCPs). Applying this filter, we removed the 1.45% of users who
performed health-related queries for more than 20% of their
searches (the same medical query percentage as used to filter HCPs
in previous work [22]). We also swept the percentage of HCPs
across the range of possible values and found that a threshold of
20% minimized the number of users excluded while still obtaining
strong predictive performance in the forecasting of unknown ADRs.
The determination of queries as healthcare-related was performed
by a proprietary classifier used by the Microsoft Bing search engine
to determine when to provide special support (e.g., instant answers
on result pages) for health-related queries. Removal of HCPs is
important given that health professionals may perform searches
for many reasons, including patient care and continuing medical
education and awareness. Also, physicians may have awareness
of ADR knowledge before such information becomes public, e.g.,
through anecdotal patient reports or the medical literature,
especially important in the prospective setting described in this
article. We focus in our efforts on ADR surveillance on the pursuit
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warning sensors based on their experiences with medications.
However, there can be value in analyzing the search activities of
HCPs for health-related studies [35]. The mean average duration
(M) of the logs for non-bot and non-HCP users was 263.57 days
(standard deviation (SD) = 198.51 days).2.2. Ground truth
The ground truth consisted of a set of drug–event pairs, each of
which was classified as either a true association or false association
based on data collected from FDA-approved product labels. The
methodology employed in the generation of this dataset is
described in detail in previous work [32]. The positive examples
were selected based on safety-related medication label changes
approved by the FDA and communicated to the public in the year
2013 through monthly summaries posted at the FDA’s MedWatch
Website [36]. The set of associations used in this work totaled 74
drug–ADR pairs, split between 15 positives cases (drawn from a
larger set of 62 positive cases that match our requirements regard-
ing the timing of when the ADR first emerged, described later) and
59 negative controls (drawn from a larger set of 75 negative pairs)
which again were filtered per the terms of our ADR analysis. In
addition to the binary labels, for the positive cases the data also
contained the month within 2013 in which the FDA label change
occurred. Since we did not want to risk using data after the label
change, we took the first day of the month in which the label
change occurred as the index date. This date was further revised
to an even earlier date as needed using the Wayback filtering
method described in detail in the next section.2.3. Wayback filtering
Web page content has been shown to change considerably over
time [37] and the content accessed on those pages can influence
future queries [38,39]. To control for confounds of Web page con-
tent associated with ADR information being present in Websites
prior to the index date, we revised the index date of the backdated
analysis for a given test case to the earlier of the label change date
or a date derived from the Internet Archive using the Wayback
Machine. Fig. 1 illustrates the process by which the index date is
revised based on the presence of the drug–ADR pair in a Web page
preceding the FDA label change date.
For each of the 39 distinct drugs in our set of positive and nega-
tive cases, we mined 18 months of query logs from the Microsoft
Bing search engine to obtain all clicked results for the union of all
queries containing the generic drug name or the brand names
under which it was marketed. Table S2 contains the generic and
the associated brand names for each drug. We considered all users’
Bing search result clicks for these queries, including those that were
only visited by a single user in the 18-month timeframe. This pro-
vided a broad range of pages that could potentially contain infor-
mation on the ADR in advance of the FDA label change date. For
each of the Web pages in the resultant set, we obtained its HTML
content using the Wayback machine, which allowed us to review
the content of the site periodically going back in time, in some cases
over 10 years. On average, sites in our dataset were crawled by the
Wayback Machine with a frequency of approximately once every
three months (M = 97.27 days, SD = 109.27 days). This is similar to
the quarterly cadence with which the FAERS data are made
available publically.
For each test case (drug–ADR pair), given the ADR, we could
therefore compute the earliest date that it was mentioned on the
previously identified sites. We automatically scraped the Websites
for co-occurrences of the drug and ADR in the content of the pageover time. Appearances of such information guided a revision of
the date to a time when suspicions or concerns regarding the
ADR emerged online. In total, 11.70% of all visited search results
contained at least one matching ADR for the drug of interest. The
ADRs and their associated synonyms are listed in Table S1 (see
Supplementary Materials). Synonyms were determined based on
manual review of authoritative medical Websites describing the
ADR as well a two-step walk on the search engine click graph sim-
ilar to previous work [40] i.e., originating with the ADR as a query,
finding all URLs in logs visited for that query, and then finding a set
of queries issued by at least 10 users resulting in visits to the same
URLs. Both the ADR and its synonyms were included in the content
analysis. In 65.6% of the original set of 62 positive pairs there was
at least one clicked result (visited by at least one user) searching
for the drug–ADR pair before the FDA label change date, and often
well before that date (M = 4.40 years, Max = 10.22 years). This find-
ing demonstrates the value of the additional refinement of the
index date to a point in time where knowledge was available in
advance of FDA labeling actions.
Positive examples were included in the set of positive cases if
one of the following three criteria were met: (1) the earliest date
from the Wayback machine analysis was between 2011 and 2013
inclusive; (2) the earliest date of the Wayback machine analysis
was after the FDA label change date, or (3) there was no record
of the ADR being associated with the drug on any Website, regard-
less of the date. 15 positive examples met these criteria and were
included in our analysis. Negative examples (59 in total) were
included based on similar criteria as positives (either (1) or (3)).
In both positives and negatives, we excluded pairs where the first
mention of the drug–ADR pair was on a Website prior to 2011
since we could not guarantee that we were removing the effect
of that information being public from our logs.2.4. Association analysis
Disproportionality analysis [32] was used to quantify the
strength of association between a given drug–ADR pair being ana-
lyzed. Specifically, we computed and used the observed-to-expected
ratio as our measure of association (signal score used in the subse-
quent ROC analysis). This generates a score for each drug–ADR pair
quantifying the extent of deviation from the expected (indepen-
dence). The higher the score, the stronger the connection between
the drug and the ADR. The outcome is one of 38 adverse events
ranging from mild (e.g., hallucinations, nocturnal enuresis) to rare
and serious (e.g., eosinophilic pneumonia, severe bullous dermati-
tis). For each drug–ADR pair and date of analysis, the observed is
the number of users that (1) search for both the drug and event
within a specified time interval following the first instance of a
search for that drug by that user, and (2) search for the drug and
ADR prior to the index date of the analysis. The time interval is
based on co-occurrence within the same: query, search session
(defined as noted earlier), day (within 24 h), week (within 7 days),
two weeks (within 14 days),month (within 30 days), or over all time
(WholeLife, i.e., the remaining duration of the log for the current
user). The average post-drug duration for the WholeLife analysis
per-user was 174.98 days (SD = 166.63 days). Since we were inter-
ested in causal associations between medications and events, we
required that the drug query preceded the ADR query chronologi-
cally in order to be included in our calculation. The expected rate is
the expected number of users that search for both the drug and
ADR under the assumption that searches for both is random. We
note that performing this type of analysis at the user level is com-
mon in other applications of search logs since it avoids skew
toward more active users, who could be overrepresented in a
query-level analysis [21,22,41].
Fig. 2. Flowchart showing the three-step process to compute signal statistics from
search logs. FDA label change dates offer useful timing information on the formal
identification and actions taken in regards to a new ADR. However, there may be
prior availability of information about the drug–ADR pair on Websites in advance of
the label change date. The availability of this information online could lead people
to query about the ADRs regardless of whether they were experiencing the ADR. To
address this potential leak of existing knowledge on searches, we considered the
date of revelation of knowledge about ADRs to be the earliest of the label change
date or the first online report of the ADR in relation to a medication.
Table 1
Performance of the models (AUROC) for different time intervals following the first
observed drug query. The time interval denotes the time in which an ADR query can
be observed.
Time interval AUROC
SameQuery 0.514
SameSession 0.580
OneDay 0.609
OneWeek 0.721
TwoWeeks 0.840
OneMonth 0.811
WholeLife 0.817
Fig. 1. Revision of the index date based on the co-occurrence of the drug–ADR pair on a Web page in Wayback analysis before the FDA label change date. Drug/ADR presence/
absence on at least one Web page at a particular point in time is highlighted with ticks (present) or crosses (absent).
R.W. White et al. / Journal of Biomedical Informatics 59 (2016) 42–48 45To account for small user counts we used the lower limit of the
observed-to-expected ratio’s 95% confidence interval (based on the
Poisson distribution) as the final signal score to be used in the
performance (ROC) analysis. Using the lower limit confidence
interval statistics instead of point estimates is a common
adjustment applied in pharmacovigilance signal detection [6] to
reduce false signals. Table S2 (Supplementary Materials) shows
the signal scores, user counts, and confidence intervals for the 74
test cases.
2.5. Scoring methodology
Fig. 2 presents a flowchart illustrating the process followed to
compute signal statistics from the search engine log data. The flow-
chart shows the filtering and adjustment of the index dates in the
ground truth using the Wayback method described earlier in this
section. The positive and negative examples that meet our criteria
are included in the evaluation set. Index dates are determined
based on drug–ADR co-occurrence on Web pages and/or the rela-
tionship between the earliest date that such co-occurrences are
observed in the Wayback machine and the label change date from
the FDA. Three years of search logs are filtered to remove bots,
inactive users, and HCPs; all of whom may bias our analyses in dif-
ferent ways. Disproportionality analysis is performed at each time
interval (SameQuery, SameSession, etc.) using the resultant logs
and our ground truth comprising 74 test cases (15 positives and
59 negative controls). The signal scores obtained from the dispro-
portionality analysis are used to rank the drug–ADR pairs and com-
pute the AUROC metrics used in evaluating signal detection
performance.
3. Results
3.1. Prospective analysis
The results of our backdated analyses of the 74 test cases com-
prising our benchmark (see Section 2) are displayed in Table 1. A
signal score for each test case was computed via disproportionality
analysis (see Section 2) [42]. The discriminatory power of ADR sig-
nals generated from our search logs signals was measured using
the area under the receiver operating characteristic (ROC) curve
(AUROC), a common performance index for signal detection in
pharmacovigilance [6,21,22]. Table 1 shows signal detection per-
formance for different time intervals between the first observation
of the drug in a user’s long-term search history and the subsequent
ADR search. For example, SameQuery describes the co-occurrence
of the drug and ADR in the same query, whereas for OneDay the
ADR search happens within 24 h of the first drug search. The time
intervals extend from SameQuery to WholeLife (i.e., the full
duration of the available log data for the drug searcher following
the first search for the medication of interest in our log data). In
ranking the test cases, we apply a correction for small user countsto score each case based on the lower 95% confidence interval of
the signal score. Although the original AUROC values are slightly
larger, none of the differences in AUROC between applying the
original signals and the adjusted signals for rankings are significant
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Fig. 3. ROC curve illustrating predictive performance using behavioral search log
data collected during the WholeLife time interval (AUROC = 0.817).
Table 2
Prospective signal detection performance of FAERS.
Year AUROC Number of reports
2013 0.84 6,268,207
2012 0.88 5,494,345
2011 0.79 4,857,012
2010 0.80 4,334,379
Aligned 0.86 N/A
46 R.W. White et al. / Journal of Biomedical Informatics 59 (2016) 42–48using DeLong’s test [43] at p < 0.05. We use the adjusted signal
scores for all of the analyses.
Table 1 shows that the AUROC for longer time intervals
(TwoWeeks or more) is higher than shorter time periods
(OneWeek or less) (all p < 0.001). The differences between the
longer time intervals are not statistically significant (all p > 0.05).
The advantage of considering longer time intervals is the potential
to find more drug searchers and more people experiencing ADRs,
and hence cover more drug–ADR pairs. Although TwoWeeks has
the highest AUROC in Table 1, two weeks may be insufficient to
observe ADRs resulting from all drugs; a 30–90 day observation
period has been more commonly used in ADR analysis [22,44]. In
fact, in previous work we have excluded activity close to the drug
search as less likely to be experiential [22]. To maximize coverage,
we focus on WholeLife for the remainder of our analysis. Fig. 3
shows the ROC curve for the WholeLife period of evaluation.
3.2. Comparison with FAERS
Table 2 displays the results of a similar analysis based on spon-
taneous reports from FDA FAERS. The analysis was based on the
same 74 test cases employed in the evaluation of the search logs.
The aim of this comparative analysis is to obtain a baseline bench-
mark for log performance and understand the difference between
our log-based method and FAERS. FAERS has a distinct advantage
for this analysis: it is one of the main sources of evidence used
by the FDA in determining label changes.
Each row of Table 2 provides the AUROC of signals generated
from FAERS by backdating the analysis to the specified year ends
(2010–2013). Each row also displays the total number of sponta-
neous reports used for the analysis at each time point. In addition,
Table 2 displays a backdated analysis using FAERS aligned to the
dates used for the WholeLife analysis of search logs (Table 1), i.e.,
label change dates revised by the Wayback Machine. The signals
were generated using FDA’s primary signal-detection algorithm:
the Multi-Item Gamma Poisson Shrinker [45,46].
A strictly fair comparison with FAERS for the task of early detec-
tion is not possible given the causal connection between FAERS
reports and label changes that is not present for the logs. For this
reason, we did not perform tests on the significance of differences
between FAERS and the logs. However, Table 2 is still informative.
The performance of search logs (AUROC = 0.82) is similar to FAERS
for detecting ADRs at least one year ahead of their publication (i.e.,
the 2010–2011 timeframe, AUROC = 0.79–0.80). The signals from
the two data sources are most comparable at this time, where sig-
nals derived from FAERS are least likely to be related to the FDA’s
decision making processes regarding label changes. We included
2010 in this analysis because the data were available in FAERS
and it provided an additional data point on the performance of
FAERS as an early detection method well before the label changes
occurred.
3.3. Varying lead times
The analysis in the previous section reported results using logs
right up until the index date. Forecasting future events well in
advance of their occurrence is an important aspect of prospective
analysis. There is value in understanding the effectiveness of our
method given different increasing lead times in advance of the
index date. We note that given the fixed duration of the log data
that we use, less log data were available as we move back in time,
potentially impacting the predictive power of the methods. Table 3
reports the performance of the search logs in predicting ADRs at
different lead times (in months) before the index date in six month
increments. There are fewer positive and negative cases as we
regress further back in time. For consistency we report the AUROCat each lead time over the 63 pairs (9 positives and 54 negatives)
(85% of the original set of pairs) for which we had behavioral
evidence in the search logs in the 24 months before the index date.
For completeness we also report the AUROC across all available
pairs at each lead time interval. The available pairs change
(increase) as the lead time drops, given the appearance of
additional behavioral evidence in the log data over time.
The results show that, while performance generally decreases
with increased lead time, we can still accurately forecast ADR well
in advance of the label changes. When focusing on the 63 pairs for
which we had evidence 24 months in advance of the label change
date, the AUROCs are often higher than that reported in Table 1.
This may be because these pairs are popular in the logs, and for
WholeLife we can make more reliable estimates of their perfor-
mance historically and even better estimates as we obtain more
data as the index date approaches. When considering all available
pairs at each lead time, there is a dip in AUROC at 18 months (i.e.,
from 0.637 at across the 63 drug–ADR pairs at 24 months to 0.568
across the 69 pairs at 18 months). During that time, six new pairs
are added for which there may be little behavioral log data. This
can lead to less reliable signal detection across the 69 pairs.
4. Discussion
We describe methods that can be used in for prospective ADR
detection scenarios where effective drug surveillance is most nec-
essary. We showed that we can reliably predict unknown adverse
drug reactions using search log data. We compared the
performance with that of FAERS and at different timeframes and
the results show that the performance of the two methods is
Table 3
Performance of the models given different lead times (t) in months before the index date. Pairs are ranked based on signal scores using the WholeLife time interval.
Lead time (t) Same pairs as t = 24 All available pairs at each t Total number of users
AUROC AUROC #Positives #Negatives #Total
None 0.883 0.817 15 59 74 57,101,343
6 months 0.858 0.775 15 59 74 52,420,889
12 months 0.759 0.635 14 57 71 43,099,412
18 months 0.669 0.568 13 56 69 33,920,410
24 months 0.637 0.637 9 54 63 24,538,372
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baseline provided by the FAERS-based prediction. The findings in
Table 1 suggest that longer time intervals (TwoWeeks or more)
result in more accurate log-based predictions. Reasons for this
include (a) more opportunity to observe the ADR, leading to larger
user counts and more reliable statistical estimates, and (b) the time
between the drug and the ADR searches may be more typical of an
individual experiencing the ADR, while shorter time intervals
(OneWeek or less) may be more likely to reflect user interests in
possible connections between the drug and the ADR.
In summary, we have demonstrated that candidate ADRs can be
detected in advance of public knowledge about the adverse effects
via a log-based signal-detection methodology. These findings res-
onate with other successes of using log-based signals in pharma-
covigilance [21,22]. However, we now show the successful
detection of ADRs that were unknown during the timeframe stud-
ied (vs. only a single drug pair in previous work [21]). This brings
the solution closer to the application scenario in which the search
logs could have strong utility: early detection of unknown ADRs, so
as to inform follow-up studies by the FDA and others. Although the
label change date reflected the time at which the FDA announced
the change publically, suspicions and concerns about the ADR that
are reported on Websites, based on signs and symptoms experi-
enced by users or scientific studies, could still be surfaced by
search engines. This information could influence search behavior
well in advance of the label change date. The use of the Internet
Archive to estimate when signals appeared in publically facing
resources retrospectively was valuable in our context and has util-
ity for other applications. For example, this technique could be
used to discount the effect of the news media and other influencing
factors on the aggregated behavioral signals that are observed in
the search logs. Although the analysis is performed using logs from
the Microsoft Bing search engine, nothing in our approach is speci-
fic to Bing. The same methods could be applied in other search
engines given longitudinal search data from their users. Only three
years of logs were available for experimentation in this study.
Longer-term data are required to make generalizable claims about
the performance of our methods, including whether the accuracy
of the predictions increases over time as more than three years
of data become available.
We note that our findings demonstrate the value of using logs
to accurately distinguish between a given reference set of posi-
tives and negatives. Thus, the methods and results were framed
by a predefined set of drug–ADR pairs of interest. Such a fixed
set of conditions and associated symptoms reduces the scope of
the surveillance challenge and thus makes the analysis computa-
tionally tractable. The challenge of discovering ADRs from large
numbers of potential drug–event pairs remains an open question.
Directions of future research include the application of the meth-
ods to new medications or to search for adverse interactions in
frequently-occurring combinations of medications. Polypharmacy
is common, especially among the elderly [47]. Applying search log
data to better understand interactions between combinations of
drugs—pairs, triples, and beyond—could help discover unknown
side effects.The risk of false positives in operational surveillance systems
run by governmental agencies and pharmaceutical companies rep-
resents a significant challenge. Each drug–ADR pair that is identi-
fied as a potential hazard poses a potentially costly challenge for
deeper examination. As such, false positives can lead to alert fati-
gue, wasted resources, and render signal detection systems
impractical. The ROC curve in Fig. 3 suggests that we can attain
reasonable recall of true positives while preserving a low false-
positive rate. For example, in fixing the false-positive rate to 0.3
(specificity: P0.7, a suggested value for clinical significance for
signal-detection assessment [48]) we can recall 86.7% of the true
positive cases in our dataset. The discrimination threshold used
in practice should be determined based on desired performance
profile of the signal detection model. The threshold could be
reduced to improve recall or increased to improve precision. Fur-
ther experiments are needed to better understand the costs that
could be incurred from mistakenly identifying drug–ADR pairs at
different rates in practice. As part of this, we need to establish
thresholds that maintain reasonable levels of tolerance with regard
to false positives while still recalling sufficient numbers of true
positives for a surveillance system based on these methods to have
practical utility.
We also note limitations in the study introduced by the data
and reference standard that we are using. For example, we only
had access to three years of search logs in total and 18 months
for any particular user; insufficient data to perform backdated
types of analysis to earlier time points. Our results are also limited
to the particular reference set used and the number of valid test
cases in that dataset.
Since we do not have ground truth about the intentions behind
people’s observed activity, we cannot be certain that they are truly
experiencing the side effects of interest. The use of ADR symptoms
reduced predictive performance, likely because symptoms can be
associated with a variety of medical conditions, only some of which
are the ADRs of interest in this study. Variations of themethods pre-
sented in this article where we target users who focus only a set of
sentinel symptoms for the duration of our observations of them in
the log data (vs. broad explorations of many symptoms) may be
valuable. We can train classifiers to identify whether a search was
experiential based on aspects of the user’s search behavior includ-
ing the recurrence of related queries over time and the content of
visited Web pages [49]. The use of specific query terminology such
as first-person statements (e.g., queries containing ‘‘I was pre-
scribed”) or those pertaining to starting a course of medications
(e.g., queries containing ‘‘first week on” or ‘‘just started”) may also
be valuable in detecting searchers who are likely to be experiencing
associated side effects.
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